A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractor...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/4/562 |
| _version_ | 1797603982026211328 |
|---|---|
| author | Wataru Kikushima Yoichi Sakurada Yoshiko Fukuda Mio Matsubara Yumi Kotoda Atsushi Sugiyama Kenji Kashiwagi |
| author_facet | Wataru Kikushima Yoichi Sakurada Yoshiko Fukuda Mio Matsubara Yumi Kotoda Atsushi Sugiyama Kenji Kashiwagi |
| author_sort | Wataru Kikushima |
| collection | DOAJ |
| description | We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractory to aflibercept were included. Patients received a mean of 30.1 aflibercept administrations for a mean 67.9-month follow-up. All patients exhibited exudation on optical coherence tomography (OCT) despite regular 4–8 weeks of aflibercept administration. Visit 1 was scheduled at the same interval from the last aflibercept injection to the baseline. The treatment interval was extended or shortened by 1–2 weeks depending on the presence or absence of exudation on OCT. After switching to brolucizumab, the follow-up interval significantly extended at 12 months (before switching: 7.6 ± 3.8 weeks vs. at 12 months: 12.1 ± 6.2 weeks, <i>p</i> = 1.3 × 10<sup>−7</sup>). Forty-three percent of the eyes achieved a dry macula at 12 months after switching. However, the best-corrected visual acuity did not improve at any visit. Morphologically, the central retinal thickness and subfoveal choroidal thickness significantly decreased from baseline at 12 months (<i>p</i> = 3.6 × 10<sup>−3</sup> and 1.0 × 10<sup>−3</sup>, respectively). Switching to brolucizumab can be considered to extend the treatment interval in eyes with exudative AMD refractory to aflibercept. |
| first_indexed | 2024-03-11T04:39:43Z |
| format | Article |
| id | doaj.art-d1dd306c8ebf421fb854d26207b8d81c |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T04:39:43Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-d1dd306c8ebf421fb854d26207b8d81c2023-11-17T20:50:40ZengMDPI AGPharmaceuticals1424-82472023-04-0116456210.3390/ph16040562A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month ResultWataru Kikushima0Yoichi Sakurada1Yoshiko Fukuda2Mio Matsubara3Yumi Kotoda4Atsushi Sugiyama5Kenji Kashiwagi6Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, JapanWe aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractory to aflibercept were included. Patients received a mean of 30.1 aflibercept administrations for a mean 67.9-month follow-up. All patients exhibited exudation on optical coherence tomography (OCT) despite regular 4–8 weeks of aflibercept administration. Visit 1 was scheduled at the same interval from the last aflibercept injection to the baseline. The treatment interval was extended or shortened by 1–2 weeks depending on the presence or absence of exudation on OCT. After switching to brolucizumab, the follow-up interval significantly extended at 12 months (before switching: 7.6 ± 3.8 weeks vs. at 12 months: 12.1 ± 6.2 weeks, <i>p</i> = 1.3 × 10<sup>−7</sup>). Forty-three percent of the eyes achieved a dry macula at 12 months after switching. However, the best-corrected visual acuity did not improve at any visit. Morphologically, the central retinal thickness and subfoveal choroidal thickness significantly decreased from baseline at 12 months (<i>p</i> = 3.6 × 10<sup>−3</sup> and 1.0 × 10<sup>−3</sup>, respectively). Switching to brolucizumab can be considered to extend the treatment interval in eyes with exudative AMD refractory to aflibercept.https://www.mdpi.com/1424-8247/16/4/562age-related macular degenerationpolypoidal choroidal vasculopathyintravitreal brolucizumab injectiontreat-and-extendswitching |
| spellingShingle | Wataru Kikushima Yoichi Sakurada Yoshiko Fukuda Mio Matsubara Yumi Kotoda Atsushi Sugiyama Kenji Kashiwagi A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result Pharmaceuticals age-related macular degeneration polypoidal choroidal vasculopathy intravitreal brolucizumab injection treat-and-extend switching |
| title | A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result |
| title_full | A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result |
| title_fullStr | A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result |
| title_full_unstemmed | A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result |
| title_short | A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result |
| title_sort | treat and extend regimen of intravitreal brolucizumab for exudative age related macular degeneration refractory to aflibercept a 12 month result |
| topic | age-related macular degeneration polypoidal choroidal vasculopathy intravitreal brolucizumab injection treat-and-extend switching |
| url | https://www.mdpi.com/1424-8247/16/4/562 |
| work_keys_str_mv | AT watarukikushima atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT yoichisakurada atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT yoshikofukuda atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT miomatsubara atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT yumikotoda atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT atsushisugiyama atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT kenjikashiwagi atreatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT watarukikushima treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT yoichisakurada treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT yoshikofukuda treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT miomatsubara treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT yumikotoda treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT atsushisugiyama treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult AT kenjikashiwagi treatandextendregimenofintravitrealbrolucizumabforexudativeagerelatedmaculardegenerationrefractorytoaflibercepta12monthresult |